NGEN (NGEN) Stock Price & Analysis
NGEN (NGEN) fell 0.55% to USD 1.81 as of June 10, 2026 at 02:24 UTC, according to Nexqual real-time market data.
NGEN last closed at USD 1.82; the session ranged USD 1.77–1.89 on volume of 616,918 shares. Market capitalization is $192.23M, with a 52-week range of USD 1.77–6.3 (NCM). Source: Nexqual, June 10, 2026 at 02:24 UTC.
Key Statistics (as of June 10, 2026 at 02:24 UTC)
| Price | USD 1.81 |
|---|---|
| Change | ▼ 0.55% (down) |
| Previous Close | USD 1.82 |
| Open | USD 1.85 |
| Day Range | USD 1.77 – 1.89 |
| 52-Week Range | USD 1.77 – 6.3 |
| Volume | 616,918 shares |
| Market Cap | $192.23M |
| Exchange | NCM |
Technical Analysis (NGEN)
Nexqual's technical model rates NGEN "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:24 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 21.71 (oversold) |
| vs SMA50 | Below (USD 3.44) |
| MACD | -0.52 (negative) |
Analyst Ratings (NGEN)
Wall Street analysts rate NGEN "None" based on 6 analysts, with a mean price target of USD 11.21 (range USD 5.03–18), per Nexqual as of June 10, 2026 at 02:24 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 11.21 |
| High Target | USD 18 |
| Low Target | USD 5.03 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (NGEN)
| Next Earnings Date | 2026-05-18 |
|---|---|
| EPS Estimate | USD -0.07 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.07 vs est -0.06 ▼ miss |
| 2025-12-31 | USD -0.27 vs est -0.07 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:24 UTC.
Financials & Fundamentals (NGEN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -1207.46% |
| Current Ratio | 1.34 |
| Total Cash | $16.56M |
| Total Debt | $0 |
| Free Cash Flow | $-13.20M |
Source: Nexqual, June 10, 2026 at 02:24 UTC.
Financial Health Score (NGEN)
Nexqual rates NGEN's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:24 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $17M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$24M |
| Efficiency | Critical — ROE -1207%, ROA -90.8% |
Ownership (NGEN)
| Insider Ownership | +20.33% |
|---|---|
| Institutional Ownership | +2.07% |
| Shares Outstanding | 106.20M |
| Float | 68.03M |
Source: Nexqual, June 10, 2026 at 02:24 UTC.
Leadership (NGEN)
NGEN is led by Adam H. Rogers, President, CEO & Chairman, per Nexqual as of June 10, 2026 at 02:24 UTC.
| President, CEO & Chairman | Adam H. Rogers |
|---|---|
| Co-Founder & Independent Director | Harold Martin Punnett D.M.D. |
| Chief Medical Advisor & Director | Randall E. Kaye (age 63) |
| Chief Financial Officer | Keith A. Vendola (age 53) |
| Senior Vice President of Patient Advocacy & Clinical Affairs | Christine McSherry |
Major Backers & Investors (NGEN)
Notable institutional backers of NGEN include Bank of America Corporation, Pfg Investments, LLC , Marshall Wace LLP, according to Nexqual as of June 10, 2026 at 02:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bank of America Corporation | 0.33% |
| Pfg Investments, LLC | 0.25% |
| Marshall Wace LLP | 0.25% |
| Royal Bank of Canada | 0.21% |
| Integrated Wealth Concepts LLC | 0.11% |
Source: Nexqual, June 10, 2026 at 02:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SLSN | Solesence, Inc. | USD 1.22 | ▼ 6.87% |
| ALTI | AlTi Global, Inc. | USD 2.81 | ▼ 5.7% |
| NVEC | NVE Corporation | USD 105.17 | ▲ 3% |
| VECO | Veeco Instruments Inc. | USD 67.19 | ▲ 14.95% |
| SKYE | Skye Bioscience, Inc. | USD 0.75 | ▲ 2.46% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:24 UTC. This page is informational and not investment advice.